News | January 24, 2025
Senores Pharmaceuticals reports revenue of Rs. 288 crore in 9M FY25
PAT after MI is Rs. 41 crore which is 162% increase
PAT after MI is Rs. 41 crore which is 162% increase
EBITDA margins expand to 31.3%
The Emcure Research Centre (ERC) will drive research across multiple dosage forms, including OSD, injectables, novel drug delivery systems (NDDS), inhalers and topical and transdermal formulations
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Scored 85/100, 2.3x the industry average in Social and 73/100, 1.8x the industry average in Governance
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
This certification will open new markets for the Kwality Pharma
The Acetaminophen and Ibuprofen tablets will be manufactured at the company’s flagship facility in KRSG, Bengaluru
The change is reflective of the company’s evolving vision aimed at further strengthening its global presence and a commitment to providing innovative solutions in the API and CDMO space
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Subscribe To Our Newsletter & Stay Updated
